AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9439561 — intervention group
Group type: COMPARATOR
Intervention: Control group (double-blind placebo or no tablets)
Number of subjects: 227
Study 7946771 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoximone
Number of subjects: 151
Study 7946771 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 151
Study 2438647 — intervention group
Group type: EXPERIMENTAL
Intervention: PCOP combination for 6 months followed by chlorambucil or CVP for 12 months
Number of subjects: 113
Study 2438647 — intervention group
Group type: EXPERIMENTAL
Intervention: PACOP for 6 months followed by chlorambucil or CVP for 12 months
Number of subjects: 113
Study 2438647 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha recombinant interferon
Number of subjects: 113
Study 2438647 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined use of interferon and chemotherapy (proposed for future trials)
Number of subjects: 113
Study 2438647 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 113
Study 27188405 — intervention group
Group type: EXPERIMENTAL
Intervention: Active stimulation
Number of subjects: 36
Study 27188405 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 36
Study 24456239 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified tubeless PCNL with tethered DJ stent
Number of subjects: 166
Study 24456239 — intervention group
Group type: COMPARATOR
Intervention: Standard PCNL with nephrostomy tube
Number of subjects: 166
Study 22424400 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behaviour group therapy (15-week manualized group therapy)
Number of subjects: 36
Study 22424400 — intervention group
Group type: COMPARATOR
Intervention: Waiting list (4 months without treatment)
Number of subjects: 36
Study 20683580 — intervention group
Group type: EXPERIMENTAL
Intervention: Indwelling urinary catheter (IUC) for 24 h
Number of subjects: 257
Study 20683580 — intervention group
Group type: EXPERIMENTAL
Intervention: Indwelling urinary catheter (IUC) for 96 h
Number of subjects: 257
Study 20683580 — intervention group
Group type: COMPARATOR
Intervention: Suprapubic urinary catheter (SUC) for 96 h
Number of subjects: 257
Study 18582254 — intervention group
Group type: EXPERIMENTAL
Intervention: mannitol 0.5 g.kg(‐1)
Number of subjects: 50
Study 18582254 — intervention group
Group type: COMPARATOR
Intervention: Hartmann's solution (control)
Number of subjects: 50
Study 15975729 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency cocaine users
Number of subjects: 54
Study 15975729 — intervention group
Group type: COMPARATOR
Intervention: Low-frequency cocaine users
Number of subjects: 54
Study 11821704 — intervention group
Group type: COMPARATOR
Intervention: High-sodium tap water (HSTW) with sodium concentration of 196 mg/l (8.5 mmol/l)
Number of subjects: 58
Study 11821704 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-sodium mineral water (LSMW) with sodium concentration of 32 mg/l (1.4 mmol/l)
Number of subjects: 58
Study 11821704 — intervention group
Group type: COMPARATOR
Intervention: Breast milk (control group)
Number of subjects: 58
Study 10443985 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive family history of alcohol abuse
Number of subjects: 270
Study 10443985 — intervention group
Group type: COMPARATOR
Intervention: No family history of alcohol abuse
Number of subjects: 270
Study 7742841 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound treatment on precooled tissue (preceded by 5 minutes of ice)
Number of subjects: 16
Study 7742841 — intervention group
Group type: COMPARATOR
Intervention: Ultrasound with no preceding treatment
Number of subjects: 16
Study 2258042 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorpheniramine (antihistamine)
Number of subjects: 12
Study 2258042 — intervention group
Group type: COMPARATOR
Intervention: Placebo (cherry syrup)
Number of subjects: 12
Study 6998304 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcendental meditation
Number of subjects: 20
Study 6998304 — intervention group
Group type: COMPARATOR
Intervention: Muscle relaxation
Number of subjects: 20
Study 31740083 — intervention group
Group type: EXPERIMENTAL
Intervention: bi-nasal short prongs
Number of subjects: 62
Study 31740083 — intervention group
Group type: COMPARATOR
Intervention: nasal mask
Number of subjects: 62
Study 31096064 — intervention group
Group type: EXPERIMENTAL
Intervention: His bundle pacing (His‐CRT)
Number of subjects: 41
Study 31096064 — intervention group
Group type: COMPARATOR
Intervention: Biventricular pacing (BiV‐CRT)
Number of subjects: 41
Study 28753064 — intervention group
Group type: COMPARATOR
Intervention: Nonoperative care
Number of subjects: 136
Study 25650051 — intervention group
Group type: EXPERIMENTAL
Intervention: 340 mg ADS‐5102
Number of subjects: 83
Study 25650051 — intervention group
Group type: EXPERIMENTAL
Intervention: 260 mg ADS‐5102
Number of subjects: 83
Study 25650051 — intervention group
Group type: EXPERIMENTAL
Intervention: 420 mg ADS‐5102
Number of subjects: 83
Study 25650051 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 83
Study 23466114 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine 20-40 mg/day
Number of subjects: 40
Study 23466114 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 21217528 — intervention group
Group type: EXPERIMENTAL
Intervention: High-pitch mode (HPM) during continuous breathing (group A)
Number of subjects: 40
Study 21217528 — intervention group
Group type: COMPARATOR
Intervention: Breath-hold mode (group B)
Number of subjects: 40
Study 21217528 — intervention group
Group type: COMPARATOR
Intervention: Standard pitch during deep-inspiratory breath-hold (group C)
Number of subjects: 40
Study 19922885 — intervention group
Group type: EXPERIMENTAL
Intervention: Live attenuated influenza vaccine (LAIV)
Number of subjects: 0
Study 19922885 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 15742768 — intervention group
Group type: EXPERIMENTAL
Intervention: Epley maneuver (canalith repositioning)
Number of subjects: 81
Study 15742768 — intervention group
Group type: COMPARATOR
Intervention: Control group (no therapy)
Number of subjects: 81
Study 12096198 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled methacholine (MCh) after allergen challenge
Number of subjects: 31
Study 12096198 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled cysteinyl leukotriene D(4) (LTD(4)) after allergen challenge
Number of subjects: 31
Study 12096198 — intervention group
Group type: COMPARATOR
Intervention: Inhaled methacholine (MCh) after control
Number of subjects: 31
Study 12096198 — intervention group
Group type: COMPARATOR
Intervention: Inhaled cysteinyl leukotriene D(4) (LTD(4)) after control
Number of subjects: 31
Study 12096198 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled cysteinyl leukotriene D(4) (LTD(4)) challenge reproducibility
Number of subjects: 31
Study 10492062 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipyrone 500 mg t.i.d.
Number of subjects: 8
Study 10492062 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 8609254 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical calcipotriene ointment (50 microgram/gm, maximum usage, 120 gm per week) for 8 weeks
Number of subjects: 78
Study 8609254 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 78
Study 1659983 — intervention group
Group type: COMPARATOR
Intervention: RESAT diet
Number of subjects: 9
Study 1659983 — intervention group
Group type: EXPERIMENTAL
Intervention: EXFIB diet
Number of subjects: 9
Study 1659983 — intervention group
Group type: COMPARATOR
Intervention: STAND diet
Number of subjects: 9
Study 7083233 — intervention group
Group type: COMPARATOR
Intervention: 5-FU alone
Number of subjects: 53
Study 7083233 — intervention group
Group type: EXPERIMENTAL
Intervention: MFC (5-FU combined with mitomycin and cytarabine)
Number of subjects: 53
Study 29953705 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-saturated fat and low-cholesterol dietary counselling
Number of subjects: 193
Study 28899771 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical debridement (MD)
Number of subjects: 70
Study 28899771 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical debridement with adjunct antimicrobial photodynamic therapy (aPDT)
Number of subjects: 70
Study 25877666 — intervention group
Group type: EXPERIMENTAL
Intervention: Terconazole vaginal suppository (80 mg for 6 days)
Number of subjects: 140
Study 25877666 — intervention group
Group type: COMPARATOR
Intervention: Oral fluconazole (150 mg, two doses)
Number of subjects: 140
Study 23704676 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin plus rosiglitazone (M + R)
Number of subjects: 699
Study 23704676 — intervention group
Group type: COMPARATOR
Intervention: Metformin
Number of subjects: 699
Study 23704676 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin plus lifestyle program (M + L)
Number of subjects: 699
Study 25885385 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramosetron 0.3 mg iv
Number of subjects: 87
Study 25885385 — intervention group
Group type: EXPERIMENTAL
Intervention: Palonosetron 0.075 mg iv
Number of subjects: 87
Study 25885385 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron 8 mg iv
Number of subjects: 87
Study 25885385 — intervention group
Group type: COMPARATOR
Intervention: Ramosetron vs Ondansetron
Number of subjects: 87
Study 25885385 — intervention group
Group type: COMPARATOR
Intervention: Ramosetron vs Palonosetron
Number of subjects: 87
Study 19483070 — intervention group
Group type: EXPERIMENTAL
Intervention: Spoon-thick consistency
Number of subjects: 61
Study 19483070 — intervention group
Group type: COMPARATOR
Intervention: Liquid consistency
Number of subjects: 61
Study 19483070 — intervention group
Group type: EXPERIMENTAL
Intervention: Bedside clinical assessment
Number of subjects: 61
Study 17526178 — intervention group
Group type: EXPERIMENTAL
Intervention: Compound E‐Bei ointment (CEBO)
Number of subjects: 120
Study 17526178 — intervention group
Group type: EXPERIMENTAL
Intervention: Daivonex
Number of subjects: 120
Study 17526178 — intervention group
Group type: COMPARATOR
Intervention: Vehicle control (placebo)
Number of subjects: 120
Study 17526178 — intervention group
Group type: EXPERIMENTAL
Intervention: CEBO
Number of subjects: 120
Study 15679526 — intervention group
Group type: EXPERIMENTAL
Intervention: Creative expression program (12-week duration)
Number of subjects: 138
Study 11803223 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 microg misoprostol
Number of subjects: 114
Study 11803223 — intervention group
Group type: COMPARATOR
Intervention: 50 microg misoprostol
Number of subjects: 114
Study 10527993 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular progesterone (i.m. progesterone-in-oil preparation)
Number of subjects: 354
Study 10527993 — intervention group
Group type: COMPARATOR
Intervention: Intravaginal progesterone
Number of subjects: 354
Study 8750402 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 3900 mg/d
Number of subjects: 37
Study 8750402 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromfenac sodium 300 mg/d
Number of subjects: 37
Study 8750402 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 1777605 — intervention group
Group type: EXPERIMENTAL
Intervention: Late intensification therapy (LIT) with high-dose methotrexate (HD-MTX) administered at 2,000 mg/m2 per dose per week, given by 24 h infusion, three doses every 12 weeks.
Number of subjects: 118
Study 1777605 — intervention group
Group type: EXPERIMENTAL
Intervention: Four or five courses of LIT with HD-MTX.
Number of subjects: 118
Study 7148411 — intervention group
Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 238
Study 31812184 — intervention group
Group type: EXPERIMENTAL
Intervention: Early introduction group (EIG)
Number of subjects: 0
Study 29897943 — intervention group
Group type: EXPERIMENTAL
Intervention: Replacing one hour of sitting with one hour of standing (intervention)
Number of subjects: 223
Study 26832746 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus reuteri DSM 17938 and Bifidobacterium longum subspecies infantis 35624 (Daily dosing)
Number of subjects: 160
Study 26832746 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus reuteri DSM 17938 and Bifidobacterium longum subspecies infantis 35624 (Weekly dosing)
Number of subjects: 160
Study 26832746 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus reuteri DSM 17938 and Bifidobacterium longum subspecies infantis 35624 (Biweekly dosing)
Number of subjects: 160
Study 26832746 — intervention group
Group type: COMPARATOR
Intervention: Control (no probiotics)
Number of subjects: 160
Study 24903522 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium (0.2 mg/kg)
Number of subjects: 70
Study 24903522 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 23269689 — intervention group
Group type: EXPERIMENTAL
Intervention: Clearfil SA
Number of subjects: 70
Study 23269689 — intervention group
Group type: EXPERIMENTAL
Intervention: RelyX
Number of subjects: 70
Study 23269689 — intervention group
Group type: COMPARATOR
Intervention: Transbond Plus and Transbond XT (control)
Number of subjects: 70
Study 20570980 — intervention group
Group type: EXPERIMENTAL
Intervention: Leader-based safety intervention encouraging safety coordinators to provide feedback on work safety to the client and line management.
Number of subjects: 6
Study 20570980 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned).
Number of subjects: 6
Study 17215587 — intervention group
Group type: EXPERIMENTAL
Intervention: Sural sensory action amplitude (SAP) and peroneal motor conduction velocity (MCV)
Number of subjects: 272
Study 15898025 — intervention group
Group type: EXPERIMENTAL
Intervention: Staff anesthesiologist (Group S)
Number of subjects: 220
Study 15898025 — intervention group
Group type: COMPARATOR
Intervention: Resident anesthesiologist (Group R)
Number of subjects: 220
Study 12297935 — intervention group
Group type: EXPERIMENTAL
Intervention: Minisite cholecystectomy (MC)
Number of subjects: 44
Study 12297935 — intervention group
Group type: COMPARATOR
Intervention: Conventional laparoscopic cholecystectomy (CLC)
Number of subjects: 44
Study 9818934 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma exchange
Number of subjects: 369
Study 9818934 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin
Number of subjects: 369
Study 9818934 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments (plasma exchange and intravenous immunoglobulin)
Number of subjects: 369
Study 9818934 — intervention group
Group type: COMPARATOR
Intervention: Inexcitable nerves group
Number of subjects: 369
Study 9818934 — intervention group
Group type: COMPARATOR
Intervention: Other groups (not inexcitable)
Number of subjects: 369
Study 9818934 — intervention group
Group type: COMPARATOR
Intervention: Axonal group
Number of subjects: 369
Study 9818934 — intervention group
Group type: COMPARATOR
Intervention: Demyelinating group
Number of subjects: 369
Study 9818934 — intervention group
Group type: EXPERIMENTAL
Intervention: Pure motor GBS patients
Number of subjects: 369
Study 7648483 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 IU salmon calcitonin (5 suppositories per week)
Number of subjects: 150
Study 7648483 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 IU salmon calcitonin (3 suppositories per week)
Number of subjects: 150
Study 7648483 — intervention group
Group type: COMPARATOR
Intervention: Placebo (5 suppositories per week)
Number of subjects: 150
Study 7648483 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups received 500 mg/day of calcium supplementation
Number of subjects: 150
Study 7648483 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 150
Study 2694201 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomipramine (CMI)
Number of subjects: 0
Study 1273220 — intervention group
Group type: EXPERIMENTAL
Intervention: Butobarbitone 100 mg
Number of subjects: 12
Study 1273220 — intervention group
Group type: EXPERIMENTAL
Intervention: Butobarbitone 200 mg
Number of subjects: 12
Study 1273220 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrazepam 5 mg
Number of subjects: 12
Study 1273220 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrazepam 10 mg
Number of subjects: 12
Study 1273220 — intervention group
Group type: COMPARATOR
Intervention: Lactose dummy treatment
Number of subjects: 12
Study 31724212 — intervention group
Group type: EXPERIMENTAL
Intervention: Entecavir (ETV) treatment
Number of subjects: 526
Study 31724212 — intervention group
Group type: EXPERIMENTAL
Intervention: Prediction model based on age, HBsAg and HBcAb quantification
Number of subjects: 526
Study 31724212 — intervention group
Group type: EXPERIMENTAL
Intervention: Prediction model
Number of subjects: 526
Study 28598775 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerised decision support system (CDSS) combined with education and feedback
Number of subjects: 20
Study 28598775 — intervention group
Group type: COMPARATOR
Intervention: Education and feedback alone
Number of subjects: 20
Study 27451467 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic alert system for OAC prescription
Number of subjects: 889
Study 24482066 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin, 500 mg daily for 30 days
Number of subjects: 39
Study 24482066 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 30 days
Number of subjects: 39
Study 22508814 — intervention group
Group type: COMPARATOR
Intervention: Accelerated radiotherapy (AR)
Number of subjects: 345
Study 22508814 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated radiotherapy plus carbogen inhalation and nicotinamide (ARCON)
Number of subjects: 345
Study 22508814 — intervention group
Group type: COMPARATOR
Intervention: Accelerated radiotherapy (AR) in patients with hypoxic tumors
Number of subjects: 345
Study 22508814 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated radiotherapy plus carbogen inhalation and nicotinamide (ARCON) in patients with hypoxic tumors
Number of subjects: 345
Study 20040610 — intervention group
Group type: EXPERIMENTAL
Intervention: Arformoterol (ARF) 15 microg
Number of subjects: 20
Study 20040610 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (NS)
Number of subjects: 20
Study 20040610 — intervention group
Group type: EXPERIMENTAL
Intervention: Arformoterol (ARF)
Number of subjects: 20
Study 17916109 — intervention group
Group type: EXPERIMENTAL
Intervention: Lubiprostone 24 mcg twice daily for 4 weeks
Number of subjects: 242
Study 17916109 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 242
Study 15777101 — intervention group
Group type: EXPERIMENTAL
Intervention: Erdosteine suspension 175mg/5mL twice daily for 1 month
Number of subjects: 23
Study 15777101 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 12875092 — intervention group
Group type: EXPERIMENTAL
Intervention: MCT/LCT lipid emulsion
Number of subjects: 72
Study 10495375 — intervention group
Group type: EXPERIMENTAL
Intervention: Finasteride 5 mg/day
Number of subjects: 0
Study 10495375 — intervention group
Group type: EXPERIMENTAL
Intervention: Finasteride 1 mg/day
Number of subjects: 0
Study 10495375 — intervention group
Group type: EXPERIMENTAL
Intervention: Finasteride 0.2 mg/day
Number of subjects: 0
Study 10495375 — intervention group
Group type: EXPERIMENTAL
Intervention: Finasteride 0.01 mg/day
Number of subjects: 0
Study 10495375 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8865634 — intervention group
Group type: EXPERIMENTAL
Intervention: Listeners' task was to indicate which complex had the greater variance in component level.
Number of subjects: 5
Study 2006245 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular scopolamine (0.3 mg, 0.6 mg)
Number of subjects: 36
Study 2006245 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral lorazepam (2 mg)
Number of subjects: 36
Study 2006245 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 7171928 — intervention group
Group type: EXPERIMENTAL
Intervention: Backwards counting while walking
Number of subjects: 0
Study 7171928 — intervention group
Group type: COMPARATOR
Intervention: Instructions to attend to orientation
Number of subjects: 0
Study 7171928 — intervention group
Group type: COMPARATOR
Intervention: No instructions given
Number of subjects: 0
Study 31235135 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention based on social cognitive theory
Number of subjects: 120
Study 28861746 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraosseous local anesthesia of the inferior alveolar nerve (IAN)
Number of subjects: 300
Study 28861746 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandibular nerve (MdN) block
Number of subjects: 300
Study 28861746 — intervention group
Group type: COMPARATOR
Intervention: Maxillary nerve (MxN) anesthesia
Number of subjects: 300
Study 27832140 — intervention group
Group type: EXPERIMENTAL
Intervention: Compensatory auditory stimulation (CAS)
Number of subjects: 14
Study 27832140 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Definition Transcranial Direct Current Stimulation (HD-tDCS)
Number of subjects: 14
Study 27832140 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of CAS and HD-tDCS
Number of subjects: 14
Study 27832140 — intervention group
Group type: COMPARATOR
Intervention: Sham control
Number of subjects: 14
Study 24630789 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel
Number of subjects: 452
Study 24630789 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 452
Study 22130393 — intervention group
Group type: EXPERIMENTAL
Intervention: Constant 10 repetition maximum (RM) load for all 3 sets and for all 3 exercises
Number of subjects: 32
Study 22130393 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% reduction after the first and second sets for all the 3 exercises
Number of subjects: 32
Study 22130393 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% reduction after the first and second sets for all the 3 exercises
Number of subjects: 32
Study 22130393 — intervention group
Group type: EXPERIMENTAL
Intervention: 15% reduction after the first and second sets for all the 3 exercises
Number of subjects: 32
Study 22130393 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% reduction after the first and second sets for free weight bench press
Number of subjects: 32
Study 20727540 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-core prostate biopsy with periprostatic nerve block
Number of subjects: 198
Study 20727540 — intervention group
Group type: COMPARATOR
Intervention: 10-core prostate biopsy without periprostatic nerve block
Number of subjects: 198